ID Analysts

Our seasoned team of analysts continually monitors investment opportunities around the world, to provide investors with the widest possible array of money-making ideas.

Analyst Articles

Several positive economic reports have led to a bullish tone in the market today, a refreshing change of pace from the action in recent sessions. Durable goods orders numbers for May came in at a healthy 3.6 percent increase; figures for May, meanwhile, were revised upward. In addition, the S&P… Read More

Earlier today we added two long positions that are attractive in their own right and could have the added tailwind of a rebound in the general stock market: The Fastenal (FAST) November 46 call option is a buy up to $3.30 per contract, the First Solar (FSLR) December 45 call… Read More

We are halving our position in Vivus (VVUS) down to approximately 3.3 percent of the portfolio. According to estimate data released by the consulting firm Symphony Health, there were about 1,180 prescriptions written for Vivus competitor Arena Pharmaceuticals’ Belviq in its first full week of availability. Read More

Buy to open the Adobe Systems (ADBE) October 44 put option. Use a limit order to pay no more than $2.80 per contract. For much of the past year, software maker Adobe Systems (ADBE) has been an outstanding performer. The stock, however, has reached unsustainably rich valuations and currently… Read More

Buy to open the Fastenal (FAST) November 46 call option. Use a limit order to pay no more than $3.30 per contract. Also buy to open the First Solar (FSLR) December 45 call option. Use a limit order to pay no more than $7.40 per contract. Fastenal (FAST) makes… Read More

With investors already jittery over the potential end of QE, Fed Chairman Bernanke rocked markets further on Wednesday by declaring a potential timetable for QE’s end. At its latest two-day meeting, the Fed’s Federal Open Market Committee decided to keep the pace of QE unchanged. However, at the press conference… Read More

US Federal Reserve officials are gathered today in Washington to hammer out monetary policy in a two-day meeting. While Fed will undoubtedly keep short-term interest rates where they are, at essentially zero, investors are eagerly waiting to learn if the central bank will scale back on its monthly asset purchases,… Read More

Although we don’t expect a material change in Fed’s policy, we don’t want to trade ahead of the statement to be released tomorrow. In the meantime, we’re holding a small handful of positions. Paychex (PAYX) has snapped back in recent sessions and should climb further still. The stock has gotten… Read More

A year ago in “Across the Street” we spoke with Matthew Norris, Portfolio Manager of Ivy Value (IYVAX). Matthew gave the nod to two stocks priced at a discount but with bright long-term outlooks. Here’s how they’ve fared. Read More